Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group. González-Peralta RP, et al. Among authors: laughlin m. Hepatology. 2005 Nov;42(5):1010-8. doi: 10.1002/hep.20884. Hepatology. 2005. PMID: 16250032 Clinical Trial.
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK; Hepatitis Interventional Therapy Group. Lindsay KL, et al. Among authors: laughlin m. Hepatology. 2001 Aug;34(2):395-403. doi: 10.1053/jhep.2001.26371. Hepatology. 2001. PMID: 11481625 Clinical Trial.
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C, Harvey J, Laughlin M. Silva M, et al. Among authors: laughlin m. J Hepatol. 2006 Aug;45(2):204-13. doi: 10.1016/j.jhep.2006.03.008. Epub 2006 Apr 18. J Hepatol. 2006. PMID: 16780997 Clinical Trial.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Among authors: laughlin m. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.
Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina JM, Livrozet JM, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C; Primoferon A Study Group. Emilie D, et al. Among authors: laughlin m. AIDS. 2001 Jul 27;15(11):1435-7. doi: 10.1097/00002030-200107270-00014. AIDS. 2001. PMID: 11504966 Clinical Trial.
The mouse metabolic phenotyping center (MMPC) live consortium: an NIH resource for in vivo characterization of mouse models of diabetes and obesity.
Laughlin M, McIndoe R, Adams SH, Araiza R, Ayala JE, Kennedy L, Lanoue L, Lantier L, Macy J, Malabanan E, McGuinness OP, Perry R, Port D, Qi N, Elias CF, Shulman GI, Wasserman DH, Lloyd KCK. Laughlin M, et al. Mamm Genome. 2024 Dec;35(4):485-496. doi: 10.1007/s00335-024-10067-y. Epub 2024 Aug 27. Mamm Genome. 2024. PMID: 39191872 Free PMC article. Review.
665 results